Evolution in the Field of HR+ Breast Cancer Management
Closing out their discussion on HR+ breast cancer management, expert panelists share their excitement for the evolving treatment paradigm.
Read More
Other Treatment Modalities for HR+ Metastatic Breast Cancer
Comprehensive discussion on novel treatment modalities in HR+ metastatic breast cancer and insight to when it is appropriate to select these agents.
Read More
HR+ Metastatic Breast Cancer: Optimal Selection of Endocrine Partners
Shared insight on the selection of endocrine partners while managing patients in the relapsed/refractory setting of HR+ metastatic breast cancer.
Read More
Advice for Community Physicians on Managing HER2+ Breast Cancer
Closing out their review on treatment strategies for HER2-expressing breast cancer, panelists share practical advice for the community setting.
Read More
Continuing CDK4/6 Inhibition at Progression of HR+ Metastatic Breast Cancer
Key opinion leaders consider when it is appropriate to continue CDK4/6 inhibition at progression of disease in the setting of HR+ metastatic breast cancer.
Read More
Molecular Testing in Relapsed/Refractory HR+ Metastatic Breast Cancer
A brief review of the role molecular profiling plays at a patient’s relapse with HR+ metastatic breast cancer.
Read More
Potential Role for T-DXd in Early-Stage HER2-Low Breast Cancer
Panelists share a brief discussion on early-stage HER2-low breast cancer and identify treatment options available in that setting.
Read More
Optimizing Real-World Management of HER2-Low Breast Cancer
Comprehensive insight on evolving management strategies for patients diagnosed with HER2-low breast cancer.
Read More
Factors in Selecting 1L Therapy for Patients With HR+ Metastatic Breast Cancer
Expert perspectives on factors that aid in the selection of optimal first-line therapy for patients with HR+ metastatic breast cancer.
Read More
HR+ Metastatic Breast Cancer: Molecular Profiling and 1L Treatment Approaches
Shifting their focus to HR+ metastatic disease, expert panelists consider the importance of molecular profiling and first-line treatment options.
Read More
Expert Perspectives on Defining HER2-Low Breast Cancer
Centered discussion on the advent of HER2-low breast cancer and how it is differentiated from HER2+ and HER2- disease.
Read More
Overview on Treatment Options for HER2+ Breast Cancer
Expert panelists provide a broad overview on HER2+ breast cancer and review the evolving treatment armamentarium.
Read More
How Clinical Trials Inform Treatment Selection in Early-Stage HR+ Breast Cancer
A brief review of prevalent clinical trials in the early-stage HR+ breast cancer paradigm and how they help to inform treatment decision-making.
Read More
Early-Stage HR+ Breast Cancer: Ki67 and the monarchE Trial
Key opinion leaders in breast cancer management discuss Ki67 and the monarchE trial, which analyzed abemaciclib therapy in the HR+ space.
Read More
How Ki67 Informs Use of Therapy in Early-Stage HR+ Breast Cancer
A broad look at the role of Ki67 expression in informing the selection of therapy for patients with early-stage HR+ breast cancer.
Read More
Best Practices for Molecular Testing in Early-Stage Breast Cancer
Expert panelists share their perspectives on best practices for molecular profiling in patients diagnosed with early-stage breast cancer.
Read More
Dr. Shiller on the Challenges in the Development of NSCLC Biomarkers
February 17th 2018Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses the difficulties that are preventing a more streamlined approached in testing for biomarkers.
Read More
Dr. Shiller on the Emergence of Liquid Biopsies
January 23rd 2018Shirley Michelle Shiller, DO, member of the Precision Medicine Institute’s Advisory Committee, Baylor University Medical Center, discusses the emerging technology of liquid biopsies and the clinical success associated with them.
Read More